Aquestive Therapeutics (AQST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on May 13. Analyst Roanna Ruiz from Leerink Partners maintained a Buy rating on the stock and has a $10.00 price target.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Roanna Ruiz’s rating is based on several strategic initiatives and financial considerations. Aquestive Therapeutics has submitted the NDA for Anaphylm, an oral epinephrine film for Type 1 allergy and anaphylaxis, to the FDA, with potential approval expected in early 2026. The company is proactively preparing for Anaphylm’s launch by engaging with payers for favorable market access and raising awareness among physicians and advocacy groups, which are positive steps towards a successful market entry.
Furthermore, Aquestive is reallocating resources by de-emphasizing their AQST-108 program in alopecia areata to focus on Anaphylm’s commercialization. This strategic shift is seen as prudent given Anaphylm’s proximity to market launch. Additionally, the company has a solid cash position expected to last into 2026, with plans to explore debt refinancing and partnerships to strengthen their financial standing. These factors contribute to Ruiz’s Buy rating, despite the lowered price target from $12 to $10.
According to TipRanks, Ruiz is an analyst with an average return of -16.1% and a 28.32% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Cytokinetics, Cormedix, and Lantheus.
In another report released yesterday, Alliance Global Partners also reiterated a Buy rating on the stock with a $4.75 price target.